Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes

Nagaoka,

doi:10.3892/ijmm.2011.662

Cited by 13 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The same group compared glucosamine hydro-chloride to N-acetylglucosamine [22] and observed no effect of N-acetylglucosamine on HA production whereas glucosamine hydrochloride appeared to modulate this parameter. The same conclusion was reached in the study by Igarashi and colleagues [21]. In contrast, another study compared the effect of native glucosamine and N-acetylglucosamine on the metabolic activity of human articular chondrocytes [26].…”

Section: Update On In Vitro Datasupporting

confidence: 68%

“…The pro-anabolic effects of glucosamine were demonstrated in both human chondrocytes and synovial cells, where glucosamine was shown to induce the production of hyaluronic acid (HA) and to directly enter the GAG biosynthetic pathway (that is, for the production of HA, keratan sulfate and sulfated GAGs) [21]. The authors also proposed that the chondroprotective effect of glucosamine results from the modulation of enzymes responsible for HA synthesis.…”

Section: Update On In Vitro Datamentioning

confidence: 99%

“…The concentrations used in the in vitro studies were 'super physiological' - in some cases up to 2,000 times higher than the maximal concentration that can realistically be achieved in plasma (10 μM) after oral administration of 1,500 mg of glucosamine sulfate in human subjects. Furthermore, some of these studies compared the effects of two formulations of glucosamine in order to provide evidence for the superiority of one or another [21,22,25,26]. It was proposed that the differences, if they truly existed, might contribute to the different results observed in clinical trials with various glucosamine formulations.…”

Section: Update On In Vitro Datamentioning

confidence: 99%

See 2 more Smart Citations

Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?

2012

View full text Add to dashboard Cite

Glucosamine in its acetylated form is a natural constituent of some glycosaminoglycans (for example, hyaluronic acid and keratan sulfate) in the proteoglycans found in articular cartilage, intervertebral disc and synovial fluid. Glucosamine can be extracted and stabilized by chemical modification and used as a drug or a nutraceutical. It has been approved for the treatment of osteoarthritis (OA) in Europe to promote cartilage and joint health and is sold over the counter as a dietary supplement in the United States. Various formulations of glucosamine have been tested, including glucosamine sulfate and glucosamine hydrochloride. In vitro and in vivo studies have uncovered glucosamine's mechanisms of action on articular tissues (cartilage, synovial membrane and subchondral bone) and justified its efficacy by demonstrating structure-modifying and anti-inflammatory effects at high concentrations. However, results from clinical trials have raised many concerns. Pharmacokinetic studies have shown that glucosamine is easily absorbed, but the current treatment doses (for example, 1,500 mg/day) barely reach the required therapeutic concentration in plasma and tissue. The symptomatic effect size of glucosamine varies greatly depending on the formulation used and the quality of clinical trials. Importantly, the effect size reduces when evidence is accumulated chronologically and evidence for the structure-modifying effects of glucosamine are sparse. Hence, glucosamine was at first recommended by EULAR and OARSI for the management of knee pain and structure improvement in OA patients, but not in the most recent NICE guidelines. Consequently, the published recommendations for the management of OA require revision. Glucosamine is generally safe and although there are concerns about potential allergic and salt-related side effects of some formulations, no major adverse events have been reported so far. This paper examines all the in vitro and in vivo evidence for the mechanism of action of glucosamine as well as reviews the results of clinical trials. The pharmacokinetics, side effects and differences observed with different formulations of glucosamine and combination therapies are also considered. Finally, the importance of study design and criteria of evaluation are highlighted as new compounds represent new interesting options for the management of OA.

show abstract

Section: Update On In Vitro Datasupporting

confidence: 68%

Section: Update On In Vitro Datamentioning

confidence: 99%

Section: Update On In Vitro Datamentioning

confidence: 99%

See 1 more Smart Citation

Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?

2012

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first study to suggest a negative effect of glucosamine. All prior studies, including those in articular cartilage, have demonstrated either no significant effect or beneficial effects on matrix homeostasis, including anti-catabolic effects, such as inhibition of matrix metalloproteinases or aggrecanases 14,15 , or improved anabolic activity 16 , In addition, our previous in vitro research on the effects of glucosamine on inflammation in the intervertebral disc paralleled evidence from articular cartilage, demonstrating anti-inflammatory activity 17,18 .…”

Section: Discussionmentioning

confidence: 78%

Glucosamine Supplementation Demonstrates a Negative Effect on Intervertebral Disc Matrix in an Animal Model of Disc Degeneration

Jacobs

Coelho³

et al. 2013

Spine

View full text Add to dashboard Cite

Study Design Laboratory based controlled in vivo study Objective To determine the in vivo effects of oral glucosamine sulfate on intervertebral disc degeneration Summary of Background Data Although glucosamine has demonstrated beneficial effect in articular cartilage, clinical benefit is uncertain. A CDC report from 2009 reported that many patients are using glucosamine supplementation for low back pain (LBP), without significant evidence to support its use. Because disc degeneration is a major contributor of LBP, we explored the effects of glucosamine on disc matrix homeostasis in an animal model of disc degeneration. Methods Eighteen skeletally mature New Zealand White rabbits were divided into four groups: control, annular puncture, glucosamine, and annular puncture+glucosamine. Glucosamine treated rabbits received daily oral supplementation with 107mg/day (weight based equivalent to human 1500mg/day). Annular puncture surgery involved puncturing the annulus fibrosus (AF) of 3 lumbar discs with a 16G needle to induce degeneration. Serial MRIs were obtained at 0, 4, 8, 12, and 20 weeks. Discs were harvested at 20 weeks for determination of glycosaminoglycan(GAG) content, relative gene expression measured by RT-PCR, and histological analyses. Results The MRI index and NP area of injured discs of glucosamine treated animals with annular puncture was found to be lower than that of degenerated discs from rabbits not supplemented with glucosamine. Consistent with this, decreased glycosaminoglycan was demonstrated in glucosamine fed animals, as determined by both histological and GAG content. Gene expression was consistent with a detrimental effect on matrix. Conclusions These data demonstrate that the net effect on matrix in an animal model in vivo, as measured by gene expression, MRI, histology, and total proteoglycan is anti-anabolic. This raises concern over this commonly used supplement, and future research is needed to establish the clinical relevance of these findings.

show abstract

“…Аминосахар глюкозамин широко используется для облегчения симптомов ОА, возможно, потому что хондроциты используют этот сахар как структурный компонент для синтеза ГАГ в ВКМ [82]. Показано, что глюкозамин уменьшает скорость пролиферации, дифференцировки и минерализации фетальных и суставных хондроцитов [83,84] путем подавления катаболических ММП, аггреканаз, провоспалительных медиаторов, а также путем индукции синтеза проанаболической гиалуроновой кислоты in vitro [85][86][87].…”

Section: функции позитивных регуляторов Mtor в хондроцитахunclassified

FUNCTIONS OF THE mTOR SIGNALING PATHWAY IN NORMAL ARTICULAR CARTILAGE CHONDROCYTES AND IN OSTEOARTHRITIS

Четина¹,

Кашеварова²,

Шарапова³

2016

rsp

View full text Add to dashboard Cite

Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes

Cited by 13 publications

References 13 publications

Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?

Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?

Glucosamine Supplementation Demonstrates a Negative Effect on Intervertebral Disc Matrix in an Animal Model of Disc Degeneration

FUNCTIONS OF THE mTOR SIGNALING PATHWAY IN NORMAL ARTICULAR CARTILAGE CHONDROCYTES AND IN OSTEOARTHRITIS

Contact Info

Product

Resources

About